Answers are grounded in this paper and cite their sources.
Model-informed drug development (MIDD) approaches receive wide regulatory acceptance in the European Medicines Agency (EMA) to support new drug development. For generic drugs, the European regulators have not reached a common position on how to use these methods. This commentary expands on the existing EMA regulatory framework for bioequivalence and physiological based pharmacokinetic (PBPK) modeling to propose conditions where mechanistic models could support or potentially waive clinical bioequivalence (BE)/bioavailability (BA) studies.
No takes yet. Share an insight, caveat, or question.
Manolis et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: